PHARMARON (03759.HK) will release its Earnings Reports on April 25.

$PHARMARON (03759.HK)$ will release its Earnings Reports on April 25th, and investors are advised to pay attention. How was the performance prior? In Q1 2024, the revenue was 2.671 billion yuan, net income was 0.216 billion yuan, and EPS was 0.130 yuan. Futubull reminds: 1. There are no hard and fast rules regarding the accounting year divisions for companies listed on the Hong Kong and US stock exchanges; it is entirely up to the company to decide, so each report period can serve as the cutoff date for the annual report without being constrained by the calendar year as the fiscal year. 2. Generally, the company will hold an earnings report meeting on the aforementioned report release date or around that date with the company's management.

Moomoo NewsApr 29 11:45 ET

PHARMARON: 2024 ANNUAL REPORT

HKEXApr 29 04:33 ET · Announcements

Zhitong Hong Kong stock short position statistics | April 28

Zhitong Hong Kong Stock Short Position Holding | April 28

Zhitong FinanceApr 28 06:30 ET

Guotou Securities: The investment and financing environment for Innovative Drugs is rebounding, CXO Orders and performance improvements are expected.

Global investment and financing in Innovative Drugs continues to improve, and a recovery in R&D demand is anticipated; new Orders are recovering in a timely manner, and there is optimism for improved CXO performance in 2025.

Zhitong FinanceApr 28 04:34 ET

Kanglong Chemical: Report for the first quarter of 2025

SZSIApr 27 12:00 ET · Announcements

PHARMARON (03759.HK) intends to appoint Wan Xuan as a non-executive Director.

On April 27, Gelonghui reported that PHARMARON (03759.HK) announced that Hu Bafeng has voluntarily resigned as a non-executive director and member of the Board of Directors' Global Strategy Committee. After Mr. Hu's resignation, he has voluntarily agreed to continue to perform the duties of non-executive director and committee member until the new non-executive director is elected by the Shareholders at the upcoming 2024 annual general meeting. On April 25, 2025, the Board of Directors reviewed and approved the proposal to nominate Wan Xuan as a candidate for the third Board of Directors as a non-executive director. The appointment of Wan Xuan as a non-executive director is subject to approval by the Shareholders at the 2024 annual general meeting.

Gelonghui FinanceApr 27 06:23 ET